Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2006

01-12-2006 | Original Article

A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4

Authors: Dhanalakshmi Chinnasamy, Matt Tector, Nachimuthu Chinnasamy, Kate Dennert, Karen M. Kozinski, Martin K. Oaks

Published in: Cancer Immunology, Immunotherapy | Issue 12/2006

Login to get access

Abstract

Fusion proteins consisting of the ligand-binding domain of CTLA4 covalently attached to an antigen (Ag) are potent immunogens. This fusion strategy effectively induces Ag-specific immunity both when introduced as a DNA-based vaccine and as a recombinant protein. CTLA4 is a ligand for B7 molecules expressed on the surface of antigen-presenting cells (APCs), and this interaction is critical for the fusion protein to stimulate Ag-specific immunity. We show that interaction of the fusion protein with either B7-1 or B7-2 is sufficient to stimulate immune activity, and that T cells are essential for the development of IgG responses. In addition, we demonstrate that human dendritic cells (DCs) pulsed with CTLA4–Ag fusion proteins can efficiently present Ag to T cells and induce an Ag-specific immune response in vitro. These studies provide further mechanistic understanding of the process by which CTLA4–Ag fusion proteins stimulate the immune system, and represent an efficient means of generating Ag-specific T cells for immunotherapy.
Literature
1.
go back to reference Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465CrossRefPubMed Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465CrossRefPubMed
2.
go back to reference Foley R, Tozer R, Wan Y (2001) Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine. Transfus Med Rev 15:292CrossRefPubMed Foley R, Tozer R, Wan Y (2001) Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine. Transfus Med Rev 15:292CrossRefPubMed
3.
go back to reference Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777CrossRefPubMed Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777CrossRefPubMed
4.
go back to reference Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328CrossRefPubMed Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328CrossRefPubMed
5.
6.
go back to reference Berg SF, Mjaaland S, Fossum S (1994) Comparing macrophages and dendritic leukocytes as antigen-presenting cells for humoral responses in vivo by antigen targeting. Eur J Immunol 24:1262PubMedCrossRef Berg SF, Mjaaland S, Fossum S (1994) Comparing macrophages and dendritic leukocytes as antigen-presenting cells for humoral responses in vivo by antigen targeting. Eur J Immunol 24:1262PubMedCrossRef
7.
go back to reference Carayanniotis G, Barber BH (1987) Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 327:59CrossRefPubMed Carayanniotis G, Barber BH (1987) Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 327:59CrossRefPubMed
8.
go back to reference Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, Howell AL (1997) Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45:146CrossRefPubMed Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, Howell AL (1997) Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45:146CrossRefPubMed
9.
go back to reference Lees A, Morris SC, Thyphronitis G, Holmes JM, Inman JK, Finkelman FD (1990) Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 145:3594PubMed Lees A, Morris SC, Thyphronitis G, Holmes JM, Inman JK, Finkelman FD (1990) Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 145:3594PubMed
10.
go back to reference Wang H, Griffiths MN, Burton DR, Ghazal P (2000) Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 97:847CrossRefPubMed Wang H, Griffiths MN, Burton DR, Ghazal P (2000) Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 97:847CrossRefPubMed
11.
go back to reference Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B (2002) A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol 14:1423CrossRefPubMed Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B (2002) A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol 14:1423CrossRefPubMed
12.
go back to reference Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17:253CrossRefPubMed Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17:253CrossRefPubMed
13.
go back to reference Boyle JS, Brady JL, Lew AM (1998) Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408CrossRefPubMed Boyle JS, Brady JL, Lew AM (1998) Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408CrossRefPubMed
14.
go back to reference Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM (2000) A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci USA 97:6676CrossRefPubMed Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM (2000) A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci USA 97:6676CrossRefPubMed
15.
go back to reference Nayak BP, Sailaja G, Jabbar AM (2003) Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4. J Virol 77:10850CrossRefPubMed Nayak BP, Sailaja G, Jabbar AM (2003) Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4. J Virol 77:10850CrossRefPubMed
16.
go back to reference Pulendran B, Palucka K, Banchereau J (2001) Sensing pathogens and tuning immune responses. Science 293:253CrossRefPubMed Pulendran B, Palucka K, Banchereau J (2001) Sensing pathogens and tuning immune responses. Science 293:253CrossRefPubMed
17.
go back to reference Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C (2001) Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22:41CrossRefPubMed Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C (2001) Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22:41CrossRefPubMed
18.
go back to reference Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519PubMed Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519PubMed
19.
go back to reference Huang TH, Wu PY, Lee CN, Huang HI, Hsieh SL, Kung J, Tao MH (2000) Enhanced antitumor immunity by fusion of CTLA4 to a self tumor antigen. Blood 96:3663PubMed Huang TH, Wu PY, Lee CN, Huang HI, Hsieh SL, Kung J, Tao MH (2000) Enhanced antitumor immunity by fusion of CTLA4 to a self tumor antigen. Blood 96:3663PubMed
20.
go back to reference Rohrbach F, Weth R, Kursar M, Sloots A, Mittrucker HW, Wels WS (2005) Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 174:5481PubMed Rohrbach F, Weth R, Kursar M, Sloots A, Mittrucker HW, Wels WS (2005) Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 174:5481PubMed
21.
go back to reference Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ (2000) A native soluble form of CTLA4. Cell Immunol 201:144CrossRefPubMed Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ (2000) A native soluble form of CTLA4. Cell Immunol 201:144CrossRefPubMed
22.
go back to reference Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ, Sharpe AH (1997) B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6:303CrossRefPubMed Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ, Sharpe AH (1997) B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6:303CrossRefPubMed
23.
go back to reference Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB (1993) Uncovering of functional alternative CTLA4 counter-receptor in B7-deficient mice. Science 262:907PubMedCrossRef Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB (1993) Uncovering of functional alternative CTLA4 counter-receptor in B7-deficient mice. Science 262:907PubMedCrossRef
24.
25.
go back to reference Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP (1994) Transplantation tolerance induced by CTLA4–Ig. Transplantation 57:1701PubMed Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP (1994) Transplantation tolerance induced by CTLA4–Ig. Transplantation 57:1701PubMed
26.
go back to reference Chaplin PJ, De Rose R, Boyle JS, McWaters P, Kelly J, Tennent JM, Lew AM, Scheerlinck JP (1999) Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun 67:6434PubMed Chaplin PJ, De Rose R, Boyle JS, McWaters P, Kelly J, Tennent JM, Lew AM, Scheerlinck JP (1999) Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun 67:6434PubMed
Metadata
Title
A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4
Authors
Dhanalakshmi Chinnasamy
Matt Tector
Nachimuthu Chinnasamy
Kate Dennert
Karen M. Kozinski
Martin K. Oaks
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0153-7

Other articles of this Issue 12/2006

Cancer Immunology, Immunotherapy 12/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine